09939.HK
Kintor Pharmaceutical Limited
HKSE · Healthcare · Biotechnology · CN
HKD 1.35
−6.25%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 89.4M | 32.7M | 5.0M | — | — |
| Cost of Revenue | 74.3M | 24.6M | 9.7M | 67.6M | 21.4M |
| Gross Profit | 15.1M | 8.0M | (4.7M) | (67.6M) | (21.4M) |
| Operating Expenses | |||||
| R&D Expense | 125.4M | 87.4M | 78.1M | 938.9M | 828.0M |
| SG&A Expense | 241.1M | 59.9M | 88.4M | 96.0M | 63.8M |
| General & Admin Expense | — | 18.7M | 61.8M | 88.4M | 43.5M |
| Selling & Marketing Expense | — | 41.2M | 26.6M | 7.0M | 20.3M |
| Other Expenses | 35.7M | 60.6M | (26.7M) | 20.2M | 52.8M |
| Total Operating Expenses | 402.3M | 207.8M | 139.8M | 1.1B | 944.5M |
| Cost and Expenses | 476.6M | 232.5M | 149.6M | 1.1B | 944.5M |
| Operating Income (EBIT) | (387.1M) | (199.8M) | (144.6M) | (1.1B) | (944.5M) |
| Non-Operating | |||||
| Interest Income | 877.6K | 105.2K | 4.2M | 13.1M | 6.9M |
| Interest Expense | 10.3M | 3.8M | 9.3M | 9.7M | 8.2M |
| Net Interest Income | (9.4M) | (3.7M) | (5.1M) | 3.4M | (1.3M) |
| Other Non-Op Income/Expense | 15.5M | (3.2M) | (10.7M) | (9.6M) | (8.8M) |
| Non-Operating Income (excl Interest) | (22.0M) | (27.3M) | 1.4M | 10.5M | 24.6M |
| EBT (Pre-Tax Income) | (371.6M) | (203.0M) | (155.3M) | (1.1B) | (953.3M) |
| Income Tax Expense | (5.8M) | 2.9M | 18.0K | (8.0M) | 1.1M |
| Bottom Line | |||||
| Net Income | (362.1M) | (200.1M) | (155.3M) | (1.1B) | (954.4M) |
| Earnings from Cont. Ops | (365.7M) | (200.1M) | (155.3M) | (1.1B) | (954.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (365.7M) | (200.1M) | (155.3M) | (1.1B) | (954.4M) |
| Per Share | |||||
| Basic EPS | (HK$0.81) | (HK$0.44) | (HK$0.36) | (HK$2.47) | (HK$2.53) |
| Diluted EPS | (HK$0.81) | (HK$0.44) | (HK$0.36) | (HK$2.47) | (HK$2.53) |
| Revenue Per Share | HK$0.18 | HK$0.07 | HK$0.01 | HK$0.00 | HK$0.00 |
| Shares | |||||
| Basic Shares Outstanding | 493.4M | 449.8M | 430.7M | 429.1M | 376.6M |
| Diluted Shares Outstanding | 493.4M | 449.8M | 430.7M | 429.1M | 376.6M |
| Profitability Metrics | |||||
| EBITDA | (302.4M) | (139.2M) | (128.4M) | (1.1B) | (950.7M) |
| D&A | 61.0M | 33.2M | 17.6M | 19.0M | 18.4M |
| EBIT | (363.4M) | (172.4M) | (146.0M) | (1.1B) | (969.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026